Jump to content
Advertisement

Advertisement
Sign in to follow this  
Health Reporter

Google-Rifaximin significantly improves bloating in IBS-D - Healio

Recommended Posts

Health Reporter

Advertisement

Rifaximin significantly improves bloating in IBS-D  Healio

In a composite of three trials, rifaximin provided a durable and significant improvement in bloating in patients with diarrhea-predominant irritable bowel syndrome as compared with placebo, according to results presented at UEG Week.

“A significantly greater percentage of patients receiving rifaximin were durable bloating responders compared to placebo using again the greater than or equal to one-point or the greater than or equal to two-point responder definition,” Brian E. Lacy, MD, PhD, from the Mayo Clinic in Jacksonville, Florida, said during his presentation. 

Lacy and colleagues identified 1,894 patients with IBS-D and randomly assigned them to rifaximin 550 mg three times daily (n = 952) or placebo for 2 weeks (n = 942) and then a 4-week treatment-free follow-up period to assess patient response. Patients answered a daily and weekly questionnaire on IBS-related bloating and relief from medication to determine their bloating severity during the first and second trial. During the third trial, bloating severity was assessed based on the patient response to questions on their bloating within 24 hours.

View the full article



Advertisement

Share this post


Link to post
Share on other sites
Sign in to follow this  

×
×
  • Create New...